Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops glycobiology-based therapies.
Year Established: | 2003 |
Funding: | 38 |
Address: | Gaithersburg, MD 20878 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 240.243.1014 |
Mail: | |
Company URL: | http://www.glycomimetics.com |
Careers at GlycoMimetics, Inc. |
Open Position: Senior Project Manager, Research To submit materials for consideration, PRINCIPALS ONLY may attach them to an e-mail message addressed to hr@glycomimetics.com with job code '103RDPM' in the subject line. NO PHONE CALLS, PLEASE. Materials and solicitations from agencies and other third parties will be discarded. Overview GlycoMimetics, Inc. (GMI) develops novel small molecule therapeutics, based on the roles that carbohydrates play in important biological processes. The company |
December 7, 2009: GlycoMimetics Announces Two Oral Presentations on Lead Drug Candidate GMI-1070 at American Society of Hematology Annual Meeting
October 20, 2009: GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round
September 2, 2009: GlycoMimetics, Inc. Announces Commencement of Pilot Study in Patients of Lead Drug Candidate for Vaso-Occlusive Crisis of Sickle Cell Disease
August 17th, 2009: GlycoMimetics, Inc. Awarded NIH Grant to Study Drug Candidate in Diabetes
July 24th, 2009: Nature Reviews: Drug Discovery Article Describes Design of Glycomimetic Compounds and Newly "Druggable" Disease Targets
May 28th, 2009: Dana-Farber Cancer Institute Presents Results of GlycoMimetics
Alliance Technology Ventures,Anthem Capital Management,Genzyme Ventures,New Enterprise Associates, Inc.,Novartis Venture Fund (FKA: Novartis Corp.)
Rachel K. King, Chief Executive Officer Before founding GlycoMimetics, Mrs. King was an Executive in Residence at New Enterprise Associates (NEA), a major venture capital firm with investments in biotechnology. Prior to joining NEA, Mrs. King was a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. (GTI) from the company's startup phase, through its IPO and later acquisition by Novartis. At GTI, she held various roles, including serving as the company's CEO. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She received her B.A degree from Dartmouth College and her MBA from Harvard Business School. Mrs. King currently serves on the Boards of Directors of MDBio and of the Biotechnology Industry Association (BIO), where she chairs the Emerging Companies Governing Body. She also serves on the Dean's Council of the Harvard School of Public Health.
John Magnani, Ph.D., Vice President and Chief Scientific Officer John Magnani is an expert in carbohydrate biology having identified and characterized many carbohydrate tumor antigens and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lewisa and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lewisa and Sialyl Lewisx and used this information to develop potent selectin inhibitors. Prior to joining GlycoMimetics, Dr. Magnani founded and led GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health. He remained at the NIH for ten years, finally serving as a tenured Research Chemist. Helen Thackray, MD, FAAP, Vice President of Drug Development Dr. Thackray joined GlycoMimetics in 2006. Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc. Prior to working at Biosynexus, Dr. Thackray served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health. Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a practicing board-certified hospital-based pediatrician. She completed a pediatrics residency at Children's National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. Dr. Thackray received her B.S from Stanford University and her M.D. from George Washington University School of Medicine. She is a member of the Institutional Review Board of the National Center for Healthcare Statistics, and is a Fellow of the American Academy of Pediatrics.